ストックスクリーナーアプリを入手
14.20
0.00%
0.00
前日終値:
$14.20
開ける：
$14
24時間の取引高:
263.70K
Relative Volume:
1.00
時価総額：
$193.43M
収益：
-
当期純損益:
$-104.29M
株価収益率:
-2.3538
EPS:
-6.0329
ネットキャッシュフロー:
$-81.45M
1週間 パフォーマンス:
+8.65%
1か月 パフォーマンス:
+21.78%
6か月 パフォーマンス:
+150.62%
1年 パフォーマンス:
+90.25%
1日の値動き範囲:
$13.71
$14.48
1週間の範囲:
$12.75
$14.59
52週間の値動き範囲:
$5.062
$15.77
Immunic Inc Stock (IMUX) Company Profile
Compare IMUX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
14.20 | 193.43M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | Stifel | Buy |
| 2026-04-15 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2026-03-24 | 開始されました | Guggenheim | Buy |
| 2025-11-07 | 開始されました | Roth Capital | Buy |
| 2025-09-29 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-25 | 開始されました | William Blair | Outperform |
| 2024-11-25 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-27 | 開始されました | B. Riley Securities | Buy |
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2021-04-15 | 開始されました | Aegis Capital | Buy |
| 2021-03-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-08-07 | 再開されました | ROTH Capital | Buy |
| 2020-07-20 | 開始されました | BMO Capital Markets | Outperform |
| 2020-06-05 | 開始されました | Wedbush | Outperform |
| 2020-05-11 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-25 | 開始されました | ROTH Capital | Buy |
| 2019-07-11 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Immunic Inc (IMUX) 最新ニュース
Immunic Inc (IMUX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immunic Inc (IMUX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunic Inc (IMUX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunic Inc (IMUX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immunic Inc (IMUX) Institutional Confidence - TradingKey
Immunic Inc (IMUX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - mcduffieprogress.com
Immunic Inc (IMUX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunic Inc (IMUX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunic Inc (IMUX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMUX - Finviz
Immunic Inc Stock (US45256V1061): Biotech share in focus after recent volatility - AD HOC NEWS
Immunic to showcase IMU-856 research at June conferences - Proactive financial news
Immunic to Participate in Investor, Industry and Scientific Conferences in June - AD HOC NEWS
Biotech firm Immunic plans IMU-856 talk at Dublin symposium - Stock Titan
IMUX Q1 2026 Earnings: Wider-Than-Expected Loss Per Share Amid Pipeline ProgressEarnings Cycle Outlook - newsline.com
IMUX Stock Price, Quote & Chart - ChartMill
Immunic stock (US45256V1061): Pipeline updates keep investor focus on late-stage catalysts - AD HOC NEWS
Immunic Inc. (IMUX) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Sharp SelloffEarnings Sentiment Score - newsline.com
Cost of goods sold of Immunic, Inc. – DUS:10V - TradingView
IMUX Q1 2026 Earnings: EPS Misses Estimates, Stock Dips 3.24%Final Results - newsline.com
IMMUNIC (IMUX) CEO Erik Lundgren files initial Form 3 insider report - Stock Titan
MS expert takes the helm - European Biotechnology Magazine
Immunic (IMUX) proxy details 6M-share plan increase and 22.2% dilution - Stock Titan
Stifel Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Immunic to Present Phase 2 CALLIPER Trial Data on Vidofludimus Calcium Impact on Neurofilament Light Chain in Progressive MS at CMSC 2026 - geneonline.com
Immunic Presents Promising Phase 2 CALLIPER Data for Vidofludimus Calcium in Progressive Multiple Sclerosis, Highlighting Safety, Efficacy, and Novel Disability Assessment Methods 1 - Minichart
Market movers: Dell, Immunic, Dollar Tree, Synopsys, Best Buy, Giyani Metals... - Proactive financial news
Immunic presents new vidofludimus calcium data at multiple sclerosis conference - Yahoo! Finance Canada
Immunic Appoints New CEO to Lead MS Strategy - The Globe and Mail
Immunic Presents Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium At Cmsc Annual Meeting - marketscreener.com
Immunic to Present Additional Phase 2 CALLIPER Data Showing Favorable Safety and Disability Signals for Vidofludimus Calcium - TradingView
New CALLIPER MS data for vidofludimus calcium at CMSC 2026 (IMUX) - Stock Titan
Progressive MS drug shows similar safety to placebo, no mood worsening 120 weeks - Stock Titan
Immunic appoints Erik Lundgren as new CEO By Investing.com - Investing.com Australia
Immunic names Erik Lundgren as CEO; Daniel Vitt steps down - MSN
Immunic Therapeutics Welcomes New CEO Erik Lundgren - Contract Pharma
Small cap wrap: Standard Uranium, Blockmate Ventures, Abacus Global, Immunic, Virtuix… - Proactive financial news
Immunic (IMUX) Appoints Erik Lundgren as New CEO Effective May 2 - GuruFocus
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial By Investing.com - Investing.com India
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial - Investing.com Australia
Immunic, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials - Yahoo Finance
Immunic lures former Roche exec Erik Lundgren to be its CEO - The Pharma Letter
Immunic Names Erik Lundgren Chief Executive - Moomoo
Erik Lundgren becomes Immunic (Nasdaq: IMUX) CEO with milestone-tied pay - Stock Titan
Immunic Inc (IMUX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):